

DERWENT-ACC-NO: 1998-230317  
DERWENT-WEEK: 199839  
COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: DNA sequence encoding BARD1, B123, BE2, BE14, BE31 or  
BE445 - which as  
breast cancer antigen, BRCA1, binding proteins are useful to  
identify patient  
having or at risk of developing cancer

INVENTOR: BAER, E; BOWCOCK, A M

PATENT-ASSIGNEE: UNIV TEXAS SYSTEM[TEXA]

PRIORITY-DATA: 1997US-0042985 (April 4, 1997) , 1996US-0025296  
(September 20,  
1996) , 1997US-0042611 (April 3, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	
PAGES	MAIN-IPC		
AU 9745866 A	April 14, 1998	N/A	000
	C12N 015/12		
WO 9812327 A2	March 26, 1998	E	347
	C12N 015/12		

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ  
DE DK EE ES FI G  
B GE GH HU ID IL IS JP KE KG KP KF KZ LC LK LR LS LT LU LV MD MG  
MK MN MW MX NO  
NE PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW  
AT BE CH DE DK  
EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG  
ZW

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO
APPL-DATE		
AU 9745866A	N/A	1997AU-0045866
September 19, 1997		
AU 9745866A	Based on	WO 9812327
N/A		
WO 9812327A2	N/A	1997WO-US16842
September 19, 1997		

INT-CL (IPC): A61K038/17; C07K014/47 ; C07K016/18 ;  
C12N015/12 ;

C12N015/62 ; C12Q001/68 ; G01N033/566 ; G01N033/68

ABSTRACTED-PUB-NO: WO 9312327A

BASIC-ABSTRACT: Nucleic acid segment comprising an isolated DNA sequence encoding BARD1, B123, BE2, BE14, BE31 or BE445, is new.

Also claimed are:

(1) a nucleic acid segment characterised as:

(a) nucleic acid segment comprising a sequence region consisting of at least 20 contiguous nucleotide that have the same sequence as, or are complementary to, 20 contiguous nucleotide from 1 of 34 nucleic acid sequences given in the specification, or

(b) nucleic acid segment of 20-20000 nucleotide that hybridises to a nucleic acid segment from 1 of the 34 nucleic acid sequences, or their complements, under standard hybridisation conditions;

(2) a recombinant host cell comprising an above described nucleic acid segment;

(3) a composition comprising isolated BARD1, B123, BE2, BE14, BE31 or BE445;

(4) an antibody (Ab) having immunospecificity for BARD1, B123, BE2, BE14, BE31 or BE445, and

(5) a method for identifying a candidate tumour suppressor gene or oncogene, comprising:

(a) obtaining a first DNA segment comprising a candidate gene, which expresses a first fusion protein comprising a transcriptional trans-activating domain attached to the candidate protein encoded by the candidate gene;

(b) obtaining a second DNA segment which expresses a second fusion protein comprising a BRCA1 or BARD1 RING domain operatively attached to a DNA binding domain that binds a defined nucleic acid sequence;

(c) providing the first and second DNA segments to a eukaryotic host cell that comprises a marker gene operatively positioned downstream of the nucleic acid sequence, and

(d) identifying an eukaryotic host cell that expresses the marker gene, thereby identifying the candidate gene as a candidate tumour suppressor gene or oncogene.

USE - The nucleic acid segments or the host cell can be used in the preparation of the recombinant breast cancer antigen, BRCA1, binding proteins BARD1, B123, BE2, BE14, BE31 or BE445, or a composition for the detection of a BARD1, B123, BE2, BE14, BE31 or BE445 nucleic acid sequence, specifically a wild type BARD1 composition for the detection or purification of BRCA1, useful to identify a patient having, or at risk of developing cancer.

BARD1 can be used in the preparation of an anti-BARD1 antibody, and in the detection and purification of a BRCA1 protein.

BARD1, B123, BE2, BE14, BE31 or BE445 can used in the identification of a binding protein agonist or antagonist that alters the binding of BARD1, B123, BE2, BE14, BE31 or BE445 to BRCA1 or the biological activity of the BRCA1-BARD1, B123, BE2, BE14, BE31 or BE445 complex.

The Ab can be used to detect BARD1, B123, BE2, BE14, BE31 or BE445, specifically an anti-BARD1 Ab can be used to identify a patient having or at risk of developing cancer (all claimed).

CHOSEN-DRAWING: Dwg.C/6

TITLE-TERMS:

DNA SEQUENCE ENCODE BREAST CANCER ANTIGEN BIND PROTEIN USEFUL  
IDENTIFY PATIENT  
RISK DEVELOP CANCER

DERWENT-CLASS: B04 D16 S03

CPI-CODES: B04-E02F; B04-F0100E; B04-G01; B04-N03; B12-K04A1;  
D05-H09;  
D05-H11A; D05-H12A; D05-H14; D05-H17A1;

EPI-CODES: S03-E14H4; S03-E14H5;

CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

M423 M710 M750 M903 N102 N135 Q233 V753

Chemical Indexing M1 \*02\*

Fragmentation Code

M423 M710 M903 N135 Q233 V754

Chemical Indexing M1 \*03\*

Fragmentation Code

M423 M710 M781 M903 N102 P831 Q233 V600 V611

Chemical Indexing M6 \*04\*

Fragmentation Code

M903 P831 Q233 R515 R521 R621 R637

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1998-071932

Non-CPI Secondary Accession Numbers: N1998-182383